



NDA 020923/S-021

**SUPPLEMENT APPROVAL**

Liebel-Flarsheim Company LLC  
Attention: Alice Lorenzo, MJ, MBe, RAC  
Compliance Officer, Director of  
Quality and Regulatory Affairs  
1034 S Brentwood Blvd, Suite 800  
Richmond Heights, MO 63117

Dear Ms. Lorenzo:

Please refer to your Supplemental New Drug Application (sNDA) dated October 16, 2017, received October 16, 2017, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Optiray (ioversol) Injection and Optiray (ioversol) Injection Pharmacy Bulk Package

This “Prior Approval” supplemental new drug application proposes the following:

<b>Labeling section</b>	<b>Information needed to be added</b>
2.1 Important Dosage and Administration Instructions	<i>Directions for Proper Use of Optiray Pharmacy Bulk Package</i> <ul style="list-style-type: none"> <li>• The container closure may be penetrated only one time, utilizing a suitable sterile transfer device or dispensing set which allows measured distribution of the contents.</li> <li>• The transferring of Optiray from the Pharmacy Bulk Package is restricted to a suitable work area, such as a laminar flow hood, utilizing aseptic technique.</li> <li>• The withdrawal of container contents should be accomplished without delay. However, should this not be possible, a maximum time of 4 hours from initial closure entry is permitted to complete fluid transfer operations.</li> <li>• Temperature of container after the closure has been entered should not exceed 25°C (77°F).</li> </ul>
<b>Labeling section</b>	<b>Information needed to be deleted</b>
16.2 Storage	<ul style="list-style-type: none"> <li>• Store up to 40°C (104°F) for up to one month in a contrast media warmer utilizing circulating warm air.</li> <li>• May store Optiray for periods longer than one month.</li> </ul>

We acknowledge your amendment on November 21, 2017.

**APPROVAL & LABELING**

We have completed our review of these supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package inserts), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf> ).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For

more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf> ).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Su-Lin Sun, PharmD, Regulatory Project Manager, by email [su-lin.sun@fda.hhs.gov](mailto:su-lin.sun@fda.hhs.gov) or by phone (301) 796-0036.

Sincerely,

*{See appended electronic signature page}*

Libero Marzella, M.D., Ph.D.  
Director  
Division of Medical Imaging Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURES:  
Content of PBP Label

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

LIBERO L MARZELLA  
12/12/2017